estramustine

Summary

Summary: A nitrogen mustard linked to estradiol, usually as phosphate; used to treat prostatic neoplasms; also has radiation protective properties.

Top Publications

  1. Gilligan T, Kantoff P. Chemotherapy for prostate cancer. Urology. 2002;60:94-100; discussion 100 pubmed
    ..Since then, it has been recognized that estramustine, when combined with a variety of microtubular inhibitors, is very active in hormone-refractory prostate cancer...
  2. Oh W, Halabi S, Kelly W, Werner C, Godley P, Vogelzang N, et al. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. Cancer. 2003;98:2592-8 pubmed
    The authors determined the safety and efficacy of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor (G-CSF) support in patients with hormone-refractory prostate carcinoma...
  3. Kreis W, Budman D, Fetten J, Gonzales A, Barile B, Vinciguerra V. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol. 1999;10:33-8 pubmed
    To apply our preclinical findings of cytotoxic synergy with the combination of estramustine phosphate (EP) and docetaxel as the basis of treatment of hormone refractory metastatic prostate cancer in man...
  4. Matsumoto A, Inoue A, Yokoi S, Nozumi K, Miyazaki K, Hosoki S, et al. Evaluation of docetaxel plus estramustine in the treatment of patients with hormone-refractory prostate cancer. Int J Urol. 2009;16:687-91 pubmed publisher
    ..Docetaxel was given at a dose of 35 mg/m(2) twice every 3 weeks and oral estramustine concurrently for three consecutive days during weeks 1 and 2 of each cycle...
  5. Fizazi K, Sikes C, Kim J, Yang J, Martinez L, Olive M, et al. High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer. Anticancer Res. 2004;24:2897-903 pubmed
    ..Finally, we studied the combination of docetaxel and estramustine on androgen-sensitive and androgen-independent cell lines in vitro and in vivo...
  6. Pienta K, Smith D. Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin. 2005;55:300-18; quiz 323-5 pubmed
    ..Building on these advances, several new traditional chemotherapeutic agents as well as new targeted therapies are under development. ..
  7. Sinibaldi V, Carducci M, Moore Cooper S, Laufer M, Zahurak M, Eisenberger M. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer. 2002;94:1457-65 pubmed
    Recent clinical trials have shown antitumor activity with the combination of docetaxel plus estramustine phosphate (EMP) in the treatment of patients with androgen independent prostate carcinoma (AIPC)...
  8. Nakabayashi M, Ling J, Xie W, Regan M, Oh W. Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer. Cancer J. 2007;13:125-9 pubmed
    Vinorelbine (VRL) in combination with estramustine has known efficacy in the initial chemotherapeutic management of hormone-refractory prostate cancer (HRPC)...
  9. Bamias A, Bozas G, Antoniou N, Poulias I, Katsifotis H, Skolarikos A, et al. Prognostic and predictive factors in patients with androgen-independent prostate cancer treated with docetaxel and estramustine: a single institution experience. Eur Urol. 2008;53:323-31 pubmed
    ..AIPC patients who were treated between March 2001 and May 2006 with biweekly docetaxel 45 mg/m(2) (day 2) and estramustine 140 mg three dimes daily (days 1-3)...

More Information

Publications62

  1. Eymard J, Priou F, Zannetti A, Ravaud A, Lepille D, Kerbrat P, et al. Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer. Ann Oncol. 2007;18:1064-70 pubmed
    ..A synergistic activity has been shown with docetaxel in combination with estramustine in vitro; however, the benefit of this combination remains controversial in clinical practice...
  2. Henriksson R, Malmström A, Bergström P, Bergh G, Trojanowski T, Andreasson L, et al. High-grade astrocytoma treated concomitantly with estramustine and radiotherapy. J Neurooncol. 2006;78:321-6 pubmed
    Experimental and early clinical investigations have demonstrated encouraging results for estramustine in the treatment of malignant glioma...
  3. Nakano K, Ohta S, Komatsu K, Kubo T, Nukui A, Suzuki K, et al. Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience. BMC Urol. 2012;12:3 pubmed publisher
    The significance of combination of docetaxel (DTX) with estramustine phosphate (EMP) in castration-resistant prostate cancer (CRPC) patients remains unclear...
  4. Suzuki M, Mamun M, Hara K, Ozeki T, Yamada Y, Kadowaki T, et al. The Val158Met polymorphism of the catechol-O-methyltransferase gene is associated with the PSA-progression-free survival in prostate cancer patients treated with estramustine phosphate. Eur Urol. 2005;48:752-9 pubmed
    The aim of our study is to find out the good responders for estramustine phosphate (EMP) therapy in patients with prostate cancer...
  5. Oudard S, Banu E, Beuzeboc P, Voog E, Dourthe L, Hardy Bessard A, et al. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol. 2005;23:3343-51 pubmed
    ..Recent clinical trials documented the high activity of the docetaxel-estramustine combination...
  6. Kikuno N, Urakami S, Nakamura S, Hiraoka T, Hyuga T, Arichi N, et al. Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer. Eur Urol. 2007;51:1252-8 pubmed
    To determine the safety and efficacy of combination chemotherapy with docetaxel (DTX), estramustine phosphate (EMP), and carboplatin (CBDCA) in patients with hormone-refractory prostate cancer (HRPC)...
  7. Petrylak D, Tangen C, Hussain M, Lara P, Jones J, Taplin M, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-20 pubmed
    ..We compared docetaxel plus estramustine with mitoxantrone plus prednisone in men with metastatic, hormone-independent prostate cancer...
  8. Noguchi M, Itoh K, Yao A, Mine T, Yamada A, Obata Y, et al. Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients. Prostate. 2005;63:1-12 pubmed
    ..antigen (HLA)-A24+ hormone refractory prostate cancer (HRPC) patients in combination with a low dose of estramustine were evaluated. Sixteen patients with HLA-A24+ HRPC were enrolled in the phase I/II study...
  9. Samelis G, Kalofonos H, Adamou A, Kosmides P, Skarlos D, Aravantinos G, et al. The combination of estramustine, vinorelbine, and mitoxantrone in hormone-refractory prostate cancer: a Phase II feasibility study conducted by the Hellenic Cooperative Oncology Group. Urology. 2005;66:382-5 pubmed
    To evaluate the safety profile and therapeutic value of the combination of estramustine, mitoxantrone, and vinorelbine in the treatment of hormone-refractory prostate cancer...
  10. Hernes E, Fossa S, Vaage S, Ogreid P, Heilo A, Paus E. Epirubicin combined with estramustine phosphate in hormone-resistant prostate cancer: a phase II study. Br J Cancer. 1997;76:93-9 pubmed
    ..Twenty-four assessable patients with hormone-resistant prostate cancer (HRPC) were to receive daily doses of oral estramustine phosphate (EMP), 10 mg kg(-1), and intravenous epirubicin (EPR) infusions, 100 mg m(-2), every third week up to ..
  11. Hudes G, Nathan F, Khater C, Haas N, Cornfield M, Giantonio B, et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol. 1997;15:3156-63 pubmed
    To evaluate the antitumor activity of 96-hour paclitaxel and daily oral estramustine phosphate (EMP) in patients with metastatic hormone-refractory prostate cancer (HRPC)...
  12. Hudes G, Haas N, Yeslow G, Gillon T, Gunnarsson P, Ellman M, et al. Phase I clinical and pharmacologic trial of intravenous estramustine phosphate. J Clin Oncol. 2002;20:1115-27 pubmed
    To determine the dose-limiting toxicities, maximum-tolerated dose, and pharmacokinetics of intravenous estramustine phosphate (IV EMP)...
  13. Picus J, Halabi S, Kelly W, Vogelzang N, Whang Y, Kaplan E, et al. A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. Cancer. 2011;117:526-33 pubmed publisher
    ..endothelial growth factor (VEGF) with bevacizumab may further enhance the antitumor effect of docetaxel and estramustine in patients with CRPC. This cooperative group trial enrolled men with CRPC...
  14. Behnam Motlagh P, Sandström P, Henriksson R, Grankvist K. Diverging effects of 5-HT3 receptor antagonists ondansetron and granisetron on estramustine-inhibited cellular potassium transport. Pharmacol Toxicol. 2001;88:244-9 pubmed
    ..specific 5-HT3-receptor antagonists, ondansetron and granisetron, with the effects of the anticancer drug, estramustine phosphate, on P31 mesothelioma cells. Estramustine phosphate (80 mg/l, 142 micromol/l) for 120 min...
  15. Pettaway C, Pisters L, Troncoso P, Slaton J, Finn L, Kamoi K, et al. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. J Clin Oncol. 2000;18:1050-7 pubmed
    ..Therapy consisted of 12 weeks of ketoconazole and doxorubicin alternating with vinblastine, estramustine, and androgen ablation followed by prostatectomy...
  16. Behnam Motlagh P, Sandström P, Henriksson R, Grankvist K. Ondansetron but not granisetron affect cell volume regulation and potassium ion transport of glioma cells treated with estramustine phosphate. J Cancer Res Clin Oncol. 2002;128:449-55 pubmed
    ..ondansetron and granisetron were therefore correlated to malignant glioma cell (Mg251) volume response to estramustine phosphate (EMP) in vitro...
  17. Narita S, Tsuchiya N, Kumazawa T, Maita S, Numakura K, Obara T, et al. Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk locali. World J Surg Oncol. 2012;10:1 pubmed publisher
    ..chemohormonal therapy comprising complete androgen blockade followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with a high risk of localized prostate cancer (PCa)...
  18. Berry D, Moinpour C, Jiang C, Ankerst D, Petrylak D, Vinson L, et al. Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J Clin Oncol. 2006;24:2828-35 pubmed
    ..of bone pain can be achieved in men with androgen-independent prostate cancer treated with docetaxel and estramustine (DE) or mitoxantrone and prednisone (MP)...
  19. Figg W, Li H, Sissung T, Retter A, Wu S, Gulley J, et al. Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. BJU Int. 2007;99:1047-55 pubmed
    To evaluate the combination of docetaxel plus estramustine (which prolongs survival in patients with androgen-independent prostate cancer, AIPC), and thalidomide (that also adds to docetaxel activity), both pre-clinically and clinically ..
  20. Kelly W, Curley T, Slovin S, Heller G, McCaffrey J, Bajorin D, et al. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol. 2001;19:44-53 pubmed
    To determine the safety and activity of weekly paclitaxel in combination with estramustine and carboplatin (TEC) in patients with advanced prostate cancer...
  21. Lubiniecki G, Berlin J, Weinstein R, Vaughn D. Thromboembolic events with estramustine phosphate-based chemotherapy in patients with hormone-refractory prostate carcinoma: results of a meta-analysis. Cancer. 2004;101:2755-9 pubmed
    Combinations of cytotoxic chemotherapy with estramustine phosphate (EMP), a nornitrogen mustard-estrogen conjugate, are used to treat patients with hormone-refractory prostate carcinoma (HRPC)...
  22. Spitaleri G, Matei D, Curigliano G, Detti S, Verweij F, Zambito S, et al. Phase II trial of estramustine phosphate and oral etoposide in patients with hormone-refractory prostate cancer. Ann Oncol. 2009;20:498-502 pubmed publisher
    ..We carried out a phase II trial to determine the activity and safety of estramustine plus oral etoposide in HRPC...
  23. Caffo O, Sava T, Comploj E, Fariello A, Zustovich F, Segati R, et al. Docetaxel, with or without estramustine phosphate, as first-line chemotherapy for hormone-refractory prostate cancer: results of a multicentre, randomized phase II trial. BJU Int. 2008;102:1080-5 pubmed publisher
    To report the results of a randomized phase II trial of docetaxel with and without estramustine phosphate (EP) in patients with hormone-refractory prostate cancer (HRPC)...
  24. Sella A, Zisman A, Kovel S, Yarom N, Leibovici D, Lindner A. Neoadjuvant chemohormonal therapy in poor-prognosis localized prostate cancer. Urology. 2008;71:323-7 pubmed publisher
    ..Complete androgen blockage and four cycles of docetaxel (70 mg/m2) on day 2 and estramustine (280 mg three times daily) on days 1 to 5 every 21 days were given to 22 patients before radical prostatectomy ..
  25. Fizazi K, Le Maitre A, Hudes G, Berry W, Kelly W, Eymard J, et al. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol. 2007;8:994-1000 pubmed
    b>Estramustine phosphate is a mustard-oestradiol conjugate, and has hormonal and non-hormonal effects. In phase II trials of patients with cancer, response to microtubule inhibitors increases when these drugs are combined with estramustine...
  26. Kim W, Whang Y, Pruthi R, Baggstrom M, Rathmell W, Rosenman J, et al. Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: a phase II trial. Urol Oncol. 2011;29:608-13 pubmed publisher
    ..v. weekly for 3 weeks and estramustine 140 mg orally 3 times daily for 3 consecutive days every 28 days prior to definitive treatment with ..
  27. Machiels J, Mazzeo F, Clausse M, Filleul B, Marcelis L, Honhon B, et al. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer. J Clin Oncol. 2008;26:5261-8 pubmed publisher
    To assess the efficacy and toxicity of the addition of estramustine to docetaxel (D) for the treatment of metastatic hormone-refractory prostate cancer...
  28. Ravery V, Fizazi K, Oudard S, Drouet L, Eymard J, Culine S, et al. The use of estramustine phosphate in the modern management of advanced prostate cancer. BJU Int. 2011;108:1782-6 pubmed publisher
    What's known on the subject? and What does the study add? Estramustine phosphate has anti-tumour properties and it improves patient outcomes if combined with other chemotherapy agents such as docetaxel...
  29. Noguchi M, Mine T, Yamada A, Obata Y, Yoshida K, Mizoguchi J, et al. Combination therapy of personalized peptide vaccination and low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients: an analysis of prognostic factors in the treatment. Oncol Res. 2007;16:341-9 pubmed
    ..prostate cancer (HRPC) under combined administration of personalized peptide vaccination and low-dose estramustine phosphate (EMP)...
  30. Li Y, Hong X, Hussain M, Sarkar S, Li R, Sarkar F. Gene expression profiling revealed novel molecular targets of docetaxel and estramustine combination treatment in prostate cancer cells. Mol Cancer Ther. 2005;4:389-98 pubmed
    Both docetaxel and estramustine are antimicrotubule agents with antitumor activity in various cancers including prostate cancer...
  31. Johansson M, Bergenheim A, Widmark A, Henriksson R. Effects of radiotherapy and estramustine on the microvasculature in malignant glioma. Br J Cancer. 1999;80:142-8 pubmed
    ..b>Estramustine has been shown to increase tumour blood flow and potentiate the effect of radiotherapy in experimental glioma...
  32. Ben Josef E, Porter A, Han S, Mertens W, Chuba P, Fontana J, et al. Neoadjuvant estramustine and etoposide followed by concurrent estramustine and definitive radiotherapy for locally advanced prostate cancer: feasibility and preliminary results. Int J Radiat Oncol Biol Phys. 2001;49:699-703 pubmed
    ..disease and to improve local control by escalating the biologic effective dose to the prostate using estramustine (EMP) concurrently with radiotherapy...
  33. Akerley W, Butera J, Wehbe T, Noto R, Stein B, Safran H, et al. A multiinstitutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone. Cancer. 2002;94:1654-60 pubmed
    b>Estramustine phosphate (EMP) and vinblastine have radiosensitizing properties and significant activity against hormone refractory prostate carcinoma...
  34. Small E, Bok R, Reese D, Sudilovsky D, Frohlich M. Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer. Semin Oncol. 2001;28:71-6 pubmed
    ..A phase I study was designed to evaluate docetaxel/estramustine plus trastuzumab, a humanized monoclonal antibody that binds to the HER2 receptor, in patients with metastatic ..
  35. Wilding G, Soulie P, Trump D, Das Gupta A, Small E. Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer. Cancer. 2006;106:1917-24 pubmed
    ..I trial, the authors evaluated the tolerability, efficacy, and pharmacokinetics of gefitinib combined with estramustine and docetaxel in patients with HRPC...
  36. Clark P, Peereboom D, Dreicer R, Levin H, Clark S, Klein E. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology. 2001;57:281-5 pubmed
    To report the results of a Phase II trial of neoadjuvant estramustine and etoposide before radical prostatectomy in patients with locally advanced disease...
  37. Zaky Ahel M, Kovacic K, Kraljic I, Tarle M. Oral estramustine therapy in serum chromogranin A-positive stage D3 prostate cancer patients. Anticancer Res. 2001;21:1475-9 pubmed
    ..with hormone refractory prostate cancer and elevated Chromogranin A (CgA) serum values were treated with estramustine for 15 months...
  38. Koie T, Ohyama C, Yamamoto H, Hatakeyama S, Yoneyama T, Hashimoto Y, et al. Safety and effectiveness of neoadjuvant luteinizing hormone-releasing hormone agonist plus low-dose estramustine phosphate in high-risk prostate cancer: a prospective single-arm study. Prostate Cancer Prostatic Dis. 2012;15:397-401 pubmed publisher
    ..efficacy and safety of neoadjuvant therapy with luteinizing hormone-releasing hormone (LHRH) agonist + low-dose estramustine phosphate (EMP) (LHRH+EMP) followed by RP. High-risk Pca was defined by the D'Amico stratification system...
  39. Sangrajrang S, Denoulet P, Laing N, Tatoud R, Millot G, Calvo F, et al. Association of estramustine resistance in human prostatic carcinoma cells with modified patterns of tubulin expression. Biochem Pharmacol. 1998;55:325-31 pubmed
    b>Estramustine (EM) is an antimicrotubule drug used in the treatment of hormone refractory advanced prostate cancer...
  40. Smith D, Dunn R, Strawderman M, Pienta K. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol. 1998;16:1835-43 pubmed
    ..To evaluate PSA as a predictor of survival, we analyzed data from sequential phase II trials of estramustine and etoposide...
  41. Carles J, Domenech M, Gelabert Mas A, Nogue M, Tabernero J, Arcusa A, et al. Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients. Acta Oncol. 1998;37:187-91 pubmed
    The purpose of this study was to evaluate the antitumor activity of vinorelbine and oral estramustine phosphate in patients with metastatic, hormone-refractory prostate cancer...
  42. Nishimura K, Nonomura N, Ono Y, Nozawa M, Fukui T, Harada Y, et al. Oral combination of cyclophosphamide, uracil plus tegafur and estramustine for hormone-refractory prostate cancer. Oncology. 2001;60:49-54 pubmed
    To evaluate the clinical usefulness of an oral combination of cyclophosphamide, uracil plus tegafur (UFT) and estramustine in the treatment of patients with hormone-refractory prostate cancer (HRPC)...
  43. Hirano D, Nagane Y, Satoh K, Mochida J, Sugimoto S, Ichinose T, et al. Neoadjuvant LHRH analog plus estramustine phosphate combined with three-dimensional conformal radiotherapy for intermediate- to high-risk prostate cancer: a randomized study. Int Urol Nephrol. 2010;42:81-8 pubmed publisher
    ..and efficacy of a treatment regimen comprising neoadjuvant conventional androgen deprivation therapy (ADT) plus estramustine phosphate (EMP) combined with three-dimensional conformal radiotherapy (3D-CRT) for patients with intermediate- ..
  44. Oudard S, Legrier M, Boye K, Bras Gonçalves R, De Pinieux G, De Cremoux P, et al. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts. J Urol. 2003;169:1729-34 pubmed
    ..Recent clinical data indicate the antitumoral efficacy of taxanes alone or combined with estramustine phosphate...
  45. Noguchi M, Itoh K, Suekane S, Morinaga A, Sukehiro A, Suetsugu N, et al. Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer. Prostate. 2004;60:32-45 pubmed
    ..who had failed to respond to the prior-peptide vaccination were entered in the combined peptide vaccination and estramustine phosphate...
  46. Ranganathan S, Dexter D, Benetatos C, Chapman A, Tew K, Hudes G. Increase of beta(III)- and beta(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance. Cancer Res. 1996;56:2584-9 pubmed
    b>Estramustine (EM), an antimicrotubule agent, is effective against hormone-refractory prostate cancer when used in combination with vinblastine or paclitaxel...
  47. Falsaperla M, Morgia G, Tartarone A, Ardito R, Romano G. Support ellagic acid therapy in patients with hormone refractory prostate cancer (HRPC) on standard chemotherapy using vinorelbine and estramustine phosphate. Eur Urol. 2005;47:449-54; discussion 454-5 pubmed
    ..to assess the effects of ellagic acid support therapy on toxicity, OR, ICR and BR in HRPC patients treated with estramustine phosphate and vinorelbine...
  48. Hirano D, Minei S, Kishimoto Y, Yamaguchi K, Hachiya T, Yoshida T, et al. Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy. Urol Int. 2005;75:43-9 pubmed
    b>Estramustine phosphate (EMP) in combination with other cytotoxic agents has been widely used in clinical trials as an anti-tumor agent for the treatment of hormone-refractory prostate cancer (HRPC)...
  49. Tucker J, Lipatova Z, Beljanski V, Townsend D, Tew K. Evaluation of lipophilins as determinants of tumor cell response to estramustine. J Pharmacol Exp Ther. 2005;315:1158-62 pubmed
    b>Estramustine administered orally as estramustine phosphate (EMP) remains a major tool in hormone refractory prostate cancer chemotherapy...
  50. Savarese D, Halabi S, Hars V, Akerley W, Taplin M, Godley P, et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol. 2001;19:2509-16 pubmed
    To investigate the combination of docetaxel, estramustine (EM), and low-dose hydrocortisone in men with hormone-refractory prostate cancer (HRPC)...
  51. Smith D, Chay C, Dunn R, Fardig J, Esper P, Olson K, et al. Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma. Cancer. 2003;98:269-76 pubmed
    ..v.) paclitaxel, carboplatin, oral etoposide, and oral estramustine (TEEC) has significant activity in patients with advanced, hormone-refractory prostate carcinoma...
  52. Alongi F, Schipani S, Samanes Gajate A, Rosso A, Cozzarini C, Fiorino C, et al. [11C]choline-PET-guided helical tomotherapy and estramustine in a patient with pelvic-recurrent prostate cancer: local control and toxicity profile after 24 months. Tumori. 2010;96:613-7 pubmed
    ..first reported case of [11C]choline positron emission tomography-guided helical tomotherapy concomitant with estramustine for the treatment of pelvic-recurrent prostate cancer...
  53. Safarinejad M. Combination chemotherapy with docetaxel, estramustine and suramin for hormone refractory prostate cancer. Urol Oncol. 2005;23:93-101 pubmed
    ..more effective chemotherapy against hormone refractory prostate cancer (HRPC) with the combination of estramustine (EM), docetaxel, and suramin...